12,851 resources
Start Prev Rows 7000 - 7200 Next
| Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Auth | Source(s) |
|---|---|---|---|---|---|---|---|---|---|
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7999 | Animal Type (Anthrax) | active | 2020-01 | sct tho | |||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1235.21 | Annual Physical CPT CN5 | active | 2023-04 | hl7 | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1235.23 | Annual Physical CPT for Tax Pair CN5 | active | 2024-06 | hl7 | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1235.30 | Annual Physical Codes for Tax Pair CN5 | active | 2024-06 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1235.22 | Annual Physical HCPCS CN5 | active | 2023-04 | hl7 | cms | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1235.17 | Annual Physical ICD10 CN5 | active | 2024-06 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1235.16 | Annual Physical ICD9 CN5 | active | 2023-04 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1235.24 | Annual Physical ICD9 for Tax Pair CN5 | active | 2024-06 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1235.18 | Annual Physical SNOMED CN5 | active | 2023-04 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1235.19 | Annual Physical Taxonomy CN5 | active | 2024-06 | hl7 | nucc | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3125 | Case Classification Exposure Source | active | 2008-01 | tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.8013 | Exposure Source (Anthrax) | active | 2020-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3089 | Interview Status | active | 2008-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3167 | Therapy Extended Reason (TB) | active | 2008-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3074 | Case Traced to Carrier | active | 2008-01 | tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3119 | Acute Convalescent IgG Difference (VPD) | active | 2008-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3166 | Cause of Death Related to TB | active | 2008-01 | tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7620 | Antacids (FDD) | active | 2017-01 | rx tho oid | |||
| hl7.fhir.us.breast-radiology | R4 | rde1559-depth | RDE1559 Depth | draft | 2022-12 | hl7 | fhir | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3212 | Signs and Symptoms (Anthrax) | active | 2009-01 | sct oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3220 | Disease Type (Anthrax) | active | 2009-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3207 | Lab Test Result Name (Anthrax) | active | 2009-01 | loinc | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3216 | Medication Treatment (Anthrax) | active | 2009-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3317 | Antimicrobial Susceptibility Test Method (IPD) | active | 2010-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3316 | Antimicrobial Agent (IPD) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.8036 | Antibiotic Dose Units (Brucellosis) | active | 2021-01 | ucum tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7693 | Antibiotic Received (RIBD) | active | 2021-01 | sct rx tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3120 | Antibiotic Received (Pertussis) | active | 2015-01 | sct rx tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7619 | Antibiotics (FDD) | active | 2018-01 | rx tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7553 | Specimen Type AST (STD) | active | 2017-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7557 | Susceptibility Test Interpretation (STD) | active | 2017-01 | sct oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7704 | Susceptibility Interpretation (RIBD) | active | 2019-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7701 | AR Test Method (RIBD) | active | 2018-01 | sct oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7556 | Susceptibility Test Method (STD) | active | 2017-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7559 | Susceptibility Test Result Quantitative (STD) | active | 2017-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7558 | Susceptibility Test Result Units (STD) | active | 2017-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7555 | Susceptibility Test Type (STD) | active | 2017-01 | loinc | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7700 | AR Agent (RIBD) | active | 2018-01 | sct rx tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.8005 | Antimicrobials (Anthrax) | active | 2020-01 | sct tho oid | |||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.45 | Endometrial Cancer ICD9 | active | 2023-11 | hl7 | icd | ||
| fhir.cdc.opioid-cds-r4 | R4 | conditions-documenting-substance-misuse | Conditions documenting substance misuse | active | 2025-04 | hl7 | sct icd | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.1045 | Specimen Risk | active | 2008-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.6038 | Morphology of Neoplasms ICD-9-CM | active | 2012-01 | fhir | |||
| hl7.fhir.us.codex-radiation-therapy | R4 | codexrt-brachytherapy-applicator-type-vs | Brachytherapy Applicator Type Value Set | active | cgp | 2025-02 | hl7 | sct | |
| us.nlm.vsac | R4 | 2.16.840.1.113883.1.11.20.2.7 | Nutritional Status | active | 2025-01 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.326 | Arboviral Disease [Other] (Disorders) (ICD10CM) | active | 2025-02 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.575 | Arboviral Disease [Other] (Tests for Arbovirus [Other] Nucleic Acid) | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.576 | Arboviral Disease [Other] (Tests for Arbovirus [Other] Antigen) | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.577 | Arboviral Disease [Other] (Tests for Arbovirus [Other] IgM Antibody) | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.578 | Arboviral Disease [Other] (Tests for Arbovirus [Other] Antibody [Quantitative]) | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.579 | Arboviral Disease [Other] (Tests for Arbovirus [Other] Antibody [Qualitative]) | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.580 | Arboviral Disease [Other] (Organism or Substance in Lab Results) | active | 2025-02 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.963 | Arboviral Disease [Other] (Disorders) (SNOMED) | active | 2025-02 | hl7 | sct | ||
| hl7.fhir.us.registry-protocols | R4 | ArterialAccessSite | Arterial Access Site | active | cic | 2023-11 | hl7 | fhir sct | |
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1186.7 | Common substances for allergy and intolerance documentation | active | 2024-06 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1186.8 | Common substances for allergy and intolerance documentation including refutations | active | 2024-06 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1115.39 | Personal Health Goal Options Grouping | active | 2025-03 | hl7 | vsac | ||
| ca.on.dhdr.r4.v4 | R4 | drug-service-coverage | Drug Service Coverage | active | hl7 | ||||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.88.12.80.60 | Social History Type (SCT) | active | 2025-04 | hl7 | sct | ||
| hl7.fhir.us.ndh | R4 | NdhAssociatedServersTypeVS | Associated Servers Type Value Set | trial-use | pa | 2025-07 | hl7 | fhir | |
| hl7.fhir.us.breast-radiology | R4 | AsymmetryAbnormalityTypeVS | Asymmetry Abnormality Type ValueSet | active | 2022-12 | hl7 | fhir | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7140 | Autopsy Planned (NCHS) | active | 2014-01 | sct | |||
| hl7.fhir.us.bser | R4 | TaskBusinessStatusVS | Task Business Status VS | draft | 2025-04 | hl7 | fhir | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3318 | Bacterial Infection Syndrome (IPD) | active | 2010-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7686 | Microorganism (RIBD) | active | 2019-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3405 | Race Category including Unknown | active | 2011-01 | tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7204 | Race Category including Refused | active | 2013-01 | tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7205 | Race Category including Null Flavor | active | 2013-01 | tho oid | |||
| hl7.fhir.us.davinci-drug-formulary | R4 | BenefitCostTypeVS | Benefit type of cost | trial-use | phx | 2025-02 | hl7 | fhir | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7903 | GC beta-lactamase result (ARLN) | active | 2019-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3323 | Birth Outcome (Rubella) | active | 2010-01 | tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7223 | Birth Status (NND) | active | 2020-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3224 | Blood or body fluid exposure event | active | 2009-01 | loinc | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3225 | Blood or body fluid exposure frequency | active | 2009-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7707 | Blood Type (RIBD) | active | 2018-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.1067 | Body Substance | active | 2010-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3117 | Body Site (FDD) | active | 2008-01 | tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7826 | Specimen Source Site (VPD) | active | 2017-12 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.967 | Body site | active | 2019-12 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3131 | Lab Result (Pertussis) | active | 2008-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3073 | Botulinum Toxin Type (FDD) | active | 2008-01 | sct tho | |||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1237.18 | Medication Prescribable Brand Name | active | 2021-06 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.88.12.80.16 | Medication Brand Name | active | 2024-06 | hl7 | rx | ||
| hl7.fhir.us.breast-radiology | R4 | BreastAssessmentCategoryVS | Breast Assessment Category ValueSet | active | 2022-12 | hl7 | fhir sct | ||
| hl7.fhir.us.breast-radiology | R4 | rde1560-breast-body-landmark | RDE1560 Breast body landmark | draft | 2022-12 | hl7 | fhir | ||
| hl7.fhir.us.breast-radiology | R4 | rde1557-side | RDE1557 Side | draft | 2022-12 | hl7 | fhir | ||
| hl7.fhir.us.directory-query | R4 | HealthcareServiceCategoryVS | Healthcare Service Category Value Set | active | 2022-12 | hl7 | fhir | ||
| hl7.fhir.us.davinci-pdex-plan-net | R4 | HealthcareServiceCategoryVS | Healthcare Service CategoryVS | trial-use | fm | 2025-02 | hl7 | fhir | |
| hl7.fhir.us.ndh | R4 | HealthcareServiceCategoryVS | Healthcare Service Category Value Set | trial-use | pa | 2025-07 | hl7 | tho | |
| signal.core.r4 | R4 | signal-healthcare-service-category | Signal Healthcare Service Category | draft | 1 | pa | hl7 | ||
| fhir.cdc.opioid-cds-r4 | R4 | opioid-treatment-assessment-procedure | Opioid treatment assessment procedure | active | 2023-05 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1010.1 | Substance Reactant for Intolerance | active | 2024-06 | hl7 | vsac | ||
| hl7.fhir.us.mcode | R4 | mcode-lymphoma-stage-bulky-modifier-vs | Lymphoma Stage Bulky Modifier Value Set | active | cic | 2025-02 | hl7 | sct | |
| hl7.fhir.us.vdor | R4 | vdor-bystanders-present-vs | VDOR Bystander(s) Present | informative | pher | 2025-06 | hl7 | fhir | |
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.88.12.3221.8.11 | Medication Product Form | active | 2024-06 | hl7 | ncit | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1045.114 | Hematocrit Lab Test | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1045.117 | Potassium Lab Test | active | 2023-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1045.119 | Sodium Lab Test | active | 2022-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1045.127 | Platelet Count Lab Test | active | 2023-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1045.129 | White Blood Cells Count Lab Test | active | 2023-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1045.134 | Glucose Lab Test | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1045.139 | Bicarbonate Lab Test | active | 2023-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1045.152 | Body Temperature | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1045.159 | Body Weight | active | 2023-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1104.10 | Medicare FFS Payer | active | 2023-02 | hl7 | |||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1104.12 | Medicare Advantage Payer | active | 2023-02 | hl7 | |||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.666.5.2363 | Creatinine Lab Test | active | 2025-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1045.151 | Oxygen Saturation by Pulse Oximetry | active | 2023-02 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.36 | All Metastatic Sites | active | 2023-10 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.43 | Breast Cancer | active | 2023-10 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.44 | Breast Cancer | active | 2023-10 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.15 | All Metastatic Sites | active | 2023-10 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.35 | All Metastatic Sites | active | 2023-10 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.39 | Locoregional Breast Cancer | active | 2023-10 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.38 | Locoregional Breast Cancer | active | 2023-10 | hl7 | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.37 | Locoregional Breast Cancer | active | 2023-10 | hl7 | sct | ||
| hl7.fhir.us.davinci-pct | R4 | PCTGFECMSPOS | PCT GFE CMS Place of Service Value Set | trial-use | fm | 2025-06 | hl7 | cms | |
| signal.core.r4 | R4 | place-of-service | Place Of Service | draft | 1 | pa | hl7 | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.229 | COVID19 Related Disease, Test, or Exposure | active | 2021-03 | hl7 | sct | ||
| hl7.fhir.us.davinci-pct | R4 | USClaimMedicalProductOrServiceCodes | Claim Medical Product or Service Value Set | trial-use | fm | 2025-06 | hl7 | cpt cms tho | |
| hl7.fhir.us.davinci-pct | R4 | PCTGFEItemCptHcpcsVS | PCT GFE Item CPT - HCPCS Value Set | trial-use | fm | 2025-06 | hl7 | cpt cms | |
| hl7.fhir.us.icsr-ae-reporting | R4 | COVID19VaccineCodeVS | COVID-19 Vaccine Codes | draft | 2023-08 | hl7 | ndc | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.996 | History Source (CRA) | active | 2008-01 | sct tho | |||
| hl7.fhir.us.registry-protocols | R4 | CardiacCTA | CTA Heart and Coronary arteries | active | cic | 2023-11 | hl7 | loinc | |
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.88.12.80.22 | CVX Vaccines Administered Complete Set | active | 2024-06 | hl7 | cvx | ||
| hl7.fhir.us.icsr-ae-reporting | R4 | VaccineCodeVS | Vaccine Codes | draft | 2023-08 | hl7 | fhir | ||
| hl7.fhir.us.icsr-ae-reporting | R4 | InfluenzaVaccineCodeVS | Influenza Vaccine Codes | draft | 2023-08 | hl7 | ndc | ||
| hl7.fhir.us.breast-radiology | R4 | CalcificationDistributionVS | CalcificationDistribution ValueSet | active | 2022-12 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1146.1189 | California Serogroup Virus Diseases (Tests for California Serogroup Virus Antibody [Qualitative]) | active | 2023-06 | hl7 | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.16 | All Metastatic Sites | active | 2023-10 | hl7 | icd | ||
| fhir.cdc.opioid-cds-r4 | R4 | cannabinoid-urine-drug-screening-tests | Cannabinoid class urine drug screening | active | 2023-05 | hl7 | loinc | ||
| hl7.fhir.us.registry-protocols | R4 | CardiacCTAResults | Cardiac CTA Results | active | cic | 2023-11 | hl7 | fhir sct | |
| hl7.fhir.us.registry-protocols | R4 | CardiacInstabilityType | Cardiac Instability Type | active | cic | 2023-11 | hl7 | fhir sct | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7272 | Case Notification MMG Version (NND) | active | 2015-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7271 | Case Notification Specification Version (NND) | active | 2015-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3138 | Relationship (VPD) | active | 2008-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7366 | Relationship (NND) | active | 2020-01 | tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3158 | Case Count Status (TB) | active | 2018-01 | tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7957 | Relationship (Hansen) | active | 2020-01 | tho | |||
| hl7.fhir.us.pco | R4 | pco-categories | Person-Centered Categories | draft | 2 | pc | 2025-03 | hl7 | fhir |
| hl7.fhir.us.directory-query | R4 | OrgAliasTypeVS | Organization Alias Typ Value Sete | active | 2022-12 | hl7 | fhir | ||
| hl7.fhir.us.ndh | R4 | OrgAliasTypeVS | Organization Alias Type Value Sete | trial-use | pa | 2025-07 | hl7 | tho | |
| hl7.fhir.us.directory-query | R4 | InsurancePlanTypeVS | Insurance Plan Type Value Set | active | 2022-12 | hl7 | fhir | ||
| hl7.fhir.us.davinci-pdex-plan-net | R4 | InsurancePlanTypeVS | Insurance Plan TypeVS | trial-use | fm | 2025-02 | hl7 | fhir | |
| hl7.fhir.us.directory-query | R4 | OrgTypeVS | Organization Type Value Set | active | 2022-12 | hl7 | fhir | ||
| hl7.fhir.us.davinci-pdex | R4 | OrgTypeVS | Organization Type VS | informative | fm | 2025-06 | hl7 | fhir | |
| hl7.fhir.us.davinci-pdex-plan-net | R4 | OrgTypeVS | Organization Type VS | trial-use | fm | 2025-02 | hl7 | fhir | |
| hl7.fhir.us.ndh | R4 | OrgTypeVS | Organization Type Value Set | trial-use | pa | 2025-07 | hl7 | fhir tho | |
| hl7.fhir.us.davinci-pct | R4 | PCTBenefitBalanceCategoryVS | PCT benefitBalance.category codes | trial-use | fm | 2025-06 | hl7 | x12 | |
| signal.core.r4 | R4 | us-core-screening-assessment-condition-category | US Core Screening Assessment Condition Category | active | 2023-04 | hl7 | fhir | ||
| signal.core.r4 | R4 | us-core-screening-assessment-observation-category | US Core Screening Assessment Observation Category | active | 2023-03 | hl7 | fhir | ||
| us.cdc.phinvads | R4 | 2.16.840.1.113883.3.2074.1.1.1 | Immunization Funding Source Excluding Nulls | active | 2012-01 | oid | |||
| hl7.fhir.us.codex-radiation-therapy | R4 | codexrt-radiotherapy-category-vs | Radiotherapy Category Code Max Value Set | active | cgp | 2025-02 | hl7 | sct | |
| hl7.fhir.us.registry-protocols | R4 | IntraAndPostEvents | Cath PCI qualified list of Events | active | cic | 2023-11 | hl7 | fhir sct | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7469 | Microcephaly Causes | active | 2016-01 | sct oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.113883.3.2074.1.1.4 | Immunization Refusal Reason Excluding Nulls | active | 2012-01 | oid | |||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1196.4502 | Ceftriaxone all code types | active | 2024-05 | hl7 | rx | ||
| hl7.fhir.us.vrdr | R4 | vrdr-certifier-types-vs | Certifier Types Value Set | active | pher | 2024-10 | hl7 | sct tho | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3055 | ECOTOX Chemicals (EPA) | active | 2008-01 | tho | |||
| hl7.fhir.us.registry-protocols | R4 | ChestPainSymptomAssessment | Chest Pain Symptom Assessment | active | cic | 2023-11 | hl7 | fhir sct | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.930 | Chest XRay Result | active | 2008-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3109 | Travelers Health Info Source | active | 2008-01 | tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3075 | Cholera Risk Factor (FDD) | active | 2008-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3076 | Cholera Sequelae (FDD) | active | 2008-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3077 | Cholera Signs Symptoms (FDD) | active | 2008-01 | sct tho | |||
| hl7.fhir.us.registry-protocols | R4 | ChronicLungDisease | Chronic Lung Disease | active | cic | 2023-11 | hl7 | sct loinc | |
| fhir.org.nz.ig.base | R4 | citizenship-status | NZ Citizenship status | active | 2025-06 | hl7 | |||
| fhir.ops-esavi | R4 | ClasificacionDesenlaceVS | Código desenlaces tras ESAVI | active | 2021-03 | hl7 | internal | ||
| signal.core.r4 | R4 | signal-filerepo-classification | Signal FileRepo Classification | draft | 2023-09 | hl7 | loinc | ||
| signal.core.r4 | R4 | questionnaire-dacods-source-of-illicit-drugs | Questionnaire DACODS Source Of Illicit Drugs | draft | 1 | pa | hl7 | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.1076 | Situation with Explicit Context | active | 2010-01 | sct | |||
| hl7.fhir.us.pacio-adi | R4 | ADIPersonalAndLegalRelationshipRoleTypeVS | Personal And Legal Relationship Role Type | active | pe | 2025-07 | hl7 | tho | |
| hl7.fhir.us.pacio-adi | R4 | ADIInterventionPreferencesOrdinalVS | Intervention Preferences - Ordinal | active | pe | 2025-07 | hl7 | loinc | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7945 | Clinical Finding (COVID-19) | active | 2020-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7832 | Clinical Manifestation (TBRD) | active | 2018-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.8008 | Clinical Manifestations (Anthrax) | active | 2020-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7541 | Clinical Manifestations (Babesiosis) | active | 2016-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.8007 | Clinical Manifestations (Brucellosis) | active | 2020-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7968 | Clinical Manifestations (Leptospirosis) | active | 2020-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7840 | Clinical Manifestations (Lyme) | active | 2018-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7989 | Clinical Outcome (Anthrax) | active | 2020-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3059 | Clinical Syndrome (Arbovirus) | active | 2016-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7195 | Clinician Observed Lesions (STD) | active | 2020-01 | sct tho oid | |||
| hl7.fhir.us.breast-radiology | R4 | rde1558-location | RDE1558 Location | draft | 2022-12 | hl7 | fhir | ||
| fhir.kenyaPSIG | R4 | CodeSystemsVS | Code Systems ValueSet | draft | 2025-07 | hl7 | internal | ||
| hl7.fhir.us.davinci-pct | R4 | PCTGFETaskRelationship | PCT GFE Task Relationship | trial-use | fm | 2025-06 | hl7 | tho | |
| hl7.fhir.us.mcode | R4 | mcode-tumor-size-method-vs | Tumor Size Method Value Set | active | 3 | cic | 2025-02 | hl7 | sct |
| us.cdc.phinvads | R4 | 2.16.840.1.113883.10.14.1.1.13.13 | Infant Fetal Complications (HL7) | active | 2017-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.113883.10.14.91 | Birth Defects Diagnostic Confirmation (HL7) | active | 2016-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.113883.3.520.4.3 | NAACCR Diagnostic Confirmation | active | 2012-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.113883.3.520.4.15 | NAACCR Grade | active | 2010-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.113883.3.520.4.12 | NAACCR Quality of Survival | active | 2010-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.113883.3.520.4.4 | NAACCR TNM Clinical Staged By | active | 2012-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.113883.3.520.4.11 | NAACCR Cancer Status | active | 2010-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.113883.3.520.4.13 | NAACCR Screening Result | active | 2010-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.113883.10.14.93 | Birth Defects Laterality at Diagnosis (HL7) | active | 2016-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.113883.3.520.4.1 | NAACCR Laterality at Diagnosis | active | 2010-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.113883.3.520.4.22 | Laterality (NAACCR) | active | 2015-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.113883.3.520.4.10 | NAACCR TNM Clinical Stage Descriptor | active | 2010-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.113883.3.520.4.21 | TNM Pathologic Stage Descriptor (NAACCR) | active | 2015-01 | oid |
FHIR